ProCE Banner Activity

BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications

Slideset Download
Download these expert-selected slides on optimal treatment of patients with B-cell malignancies with BTK inhibitors

Released: June 11, 2021

Expiration: June 10, 2022

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Janssen administered by Scientific Affairs

Pharmacyclics AbbVie

Program Director Disclosure

Program Director

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio